New CGM device developed in Wales removes need to use needles for people living with diabetes on insulin
The CGM device closely resembles a wristwatch
Professor de Vries, Medical Director at Profil, the diabetes research organisation in Germany specialising in internal medicine and endocrinology, and principal investigator at the University of Amsterdam's Faculty of Medicine, said: “We evaluated the Afon device under both hyper-and hypoglycaemic (high and low blood glucose levels) conditions during the clinical trials and we were surprised and excited by the possibilities of this technology.”
The product will be designed to alert the user when they have high and low glucose levels and will also help to monitor personalised health trends.
Not only that, but the smart technology has been neatly designed to fit inside a wristwatch strap to communicate with the user’s choice of smartwatch or smart device. With no replaceable parts it will be cheaper than other current diabetes technologies available on the market which rely on replacement patches and needles.
Companies like Apple, Samsung and Google are rumoured to have been trying to develop non-invasive blood glucose monitoring, but so far none have been successful. Afon Technology hopes to win the race to this important milestone.
Afon Technology’s CEO Sabih Chaudhry said: “Our taskforce of experts are world-class and together we’re proud to be developing a global first. Our recent clinical trials have gone really well and we’re excited to be bringing this device, which is the next big thing in diabetes technology, to people very soon.
“Diabetes can be incredibly limiting to someone’s life, but we believe we’ve created a device which will provide the wonderful feeling of freedom all wrapped up in a watch on the wrist.”
It is hoped the device, which is set to undergo another round of clinical trials, will be available to purchase from mid-2022.
According to research £5.5 billion of the NHS hospitals budget is spent on diabetes, and poor diabetes control was responsible for £3 billion in potentially avoidable hospital treatment in England in the year 2017-2018.
The company, founded in 2015 and based in Wales, has already scooped a major industry prize, picking up a Healthcare and Pharmaceutical Award.